In February 2023, the professional team from VCRO assisted the client in submitting an allogeneic umbilical cord mesenchymal stem cell product for clinical trials in the field of cardiovascular diseases to TFDA. The team successfully obtained TFDA approval to proceed with Phase I clinical trials, helping the client smoothly transition to the clinical trial phase.
Congratulations! Allogeneic stem cell for cardiovascular disease treatment has received TFDA approval for Phase I clinical trial!
In February 2023, the professional team from VCRO assisted the client in submitting an allogeneic umbilical cord mesenchymal stem cell product for clinical trials in the field of cardiovascular diseases to TFDA. The team successfully obtained TFDA approval to proceed with Phase I clinical trials, helping the client smoothly transition to the clinical trial phase.